Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination
← catalyst calendarNCT07154810 · readout in 1,698 d
Sponsored by SpyGlass Pharma, Inc. (industry) · SGP — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
23actual
Sites
1
Country
Honduras
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-16 | actual | When the study began enrolling |
| Primary completion | 2031-04-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-04-14 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Glaucoma
- Cataract
- Ocular Hypertension
Primary outcome
what the primary-completion date above is the date OFUnmedicated eyes with an IOP Reduction from SGP-SPEC-001 Baseline
measured From Month 9 post-operative through the end of post-operative follow-up at Month 84
Publications
- PMID 41621045 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · SGP's whole pipeline · Catalyst calendar · Every registered study · What changed